TMCI Stock Forecast & Price Target

Treace Medical Concepts Inc. has demonstrated a notable increase in active surgeon users, which rose by 7.0% year-over-year, highlighting an expanding adoption of its patented Lapiplasty 3D Bunion Correction procedure. The company’s proactive strategies, including enhanced direct-to-consumer marketing and increased physician education, position it well for future revenue growth, particularly in the highly competitive HV market. Additionally, the expansion of its product offerings beyond Lapiplasty and bolstered salesforce efforts suggest potential for increased margins and overall revenue growth in the coming fiscal years.

Treace Medical Concepts Inc. is facing a challenging financial outlook, with a projected revenue decline of approximately 10% year-over-year for the fourth quarter, historically considered the strongest period for the company. The company has also lowered its fiscal year 2025 revenue guidance to between $211 and $213 million, down from a previous estimate of $224 to $230 million, primarily due to declining bunion procedure volumes as customers defer elective surgeries. Additionally, with expectations of negative year-over-year growth in 2026 and multiple compressions anticipated in the near future, the overall market sentiment suggests a prolonged period of financial underperformance for Treace Medical Concepts.